title: Association between microsomal epoxide hydrolase 1 T113C polymorphism and susceptibility to lung cancer.
abstract: Previous case-control studies assessing the association between microsomal epoxide hydrolase 1 (EPHX1) T113C and susceptibility to lung cancer reported conflicting results. Thus, a systemic review and meta-analysis of published studies were performed to assess the possible association. PubMed and Embase databases were searched for all eligible studies. The strength of the association between EPHX1 T113C polymorphism and lung cancer risk was estimated by the pooled odds ratios (ORs) with its 95 % confidence interval. Twenty-four individual case-control studies involving a total of 4,970 lung cancer cases and 8,917 controls were finally included into the meta-analysis. When all 24 studies were included into the meta-analysis, the pooled results suggested that there was no association between EPHX1 T113C polymorphism and lung cancer risk under all four comparison models, and all P values for the pooled ORs were more than 0.05. In the subgroup analysis of Caucasians, the pooled results suggested that EPHX1 T113C polymorphism was associated with decreased risk of lung cancer under all four comparison models, and all P values for the pooled ORs were less than 0.05. However, in the subgroup analysis of Asians, the pooled results suggested that EPHX1 T113C polymorphism was associated with increased risk of lung cancer under three comparison models, and all P values for the pooled ORs were less than 0.05. There was no risk of publication bias. This current meta-analysis suggests that EPHX1 T113C polymorphism is associated with lung cancer risk, and there is an obvious race-specific effect in the association.
authors: Department of Emergency, Fourth Affiliated Hospital of China Medical University, No. 102 Nan Qi Road, Heping District, Shenyang City, 110005, Liaoning Province, People's Republic of China. doctorcmu@126.com
authors: Siwen
authors: S
authors: Wang
authors: Jie
authors: J
authors: Zhu
authors: Ruxin
authors: R
authors: Zhang
authors: Siyang
authors: S
authors: Wang
authors: Zongheng
authors: Z
authors: Gu
mesh_terms: D016022:Case-Control Studies; D004851:Epoxide Hydrolases / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D008175:Lung Neoplasms / Q000209:etiology*; D011110:Polymorphism, Genetic / Q000235:genetics*; D012196:Review Literature as Topic; D012307:Risk Factors
chemical_list: D004851:Epoxide Hydrolases; C522330:EPHX1 protein, human
references: Epidemiology. 2006 Jan;17(1):89-99
references: 16357600
references: Lung Cancer. 2001 Aug-Sep;33(2-3):133-41
references: 11551408
references: Tumori. 2010 Sep-Oct;96(5):756-63
references: 21302624
references: Tumour Biol. 2013 Feb;34(1):155-63
references: 23055191
references: PLoS One. 2011;6(12):e29431
references: 22206016
references: Lancet. 2011 Nov 12;378(9804):1727-40
references: 21565398
references: Br J Cancer. 2003 Aug 18;89(4):702-6
references: 12915882
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Int J Cancer. 2010 Oct 1;127(7):1547-61
references: 20091863
references: Carcinogenesis. 2001 Jun;22(6):923-8
references: 11375900
references: Mol Carcinog. 2002 Feb;33(2):99-104
references: 11813302
references: Cancer Lett. 2006 Jun 8;237(1):102-8
references: 16005144
references: Nat Rev Immunol. 2009 May;9(5):377-84
references: 19330016
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Arch Toxicol. 2009 Apr;83(4):297-318
references: 19340413
references: Eur J Cancer Prev. 2005 Jun;14(3):223-30
references: 15901990
references: Respirology. 2008 Nov;13(6):837-50
references: 18811882
references: Lancet. 1997 Aug 30;350(9078):630-3
references: 9288046
references: Int J Mol Med. 2000 Jan;5(1):49-53
references: 10601573
references: Tumour Biol. 2012 Dec;33(6):2385-92
references: 22965879
references: Tumour Biol. 2012 Oct;33(5):1467-76
references: 22528945
references: Drug Metab Rev. 2003 Nov;35(4):365-83
references: 14705866
references: Tumour Biol. 2012 Dec;33(6):1973-81
references: 22797821
references: Lung Cancer. 2000 May;28(2):147-55
references: 10717332
references: Cancer Invest. 2011 Jul;29(6):411-8
references: 21649467
references: Int J Cancer. 1999 May 5;81(3):325-9
references: 10209943
references: Carcinogenesis. 2007 Jun;28(6):1287-93
references: 17259654
references: Tumour Biol. 2012 Apr;33(2):523-35
references: 22161138
references: BMC Cancer. 2008 Feb 25;8:60
references: 18298806
references: Yi Chuan. 2004 Sep;26(5):584-8
references: 15640066
references: Wei Sheng Yan Jiu. 2012 Mar;41(2):251-6
references: 22611936
references: Cancer Res. 1998 Dec 1;58(23):5291-3
references: 9850050
references: Environ Mol Mutagen. 2004;44(1):74-82
references: 15199549
references: Lung Cancer. 2009 Feb;63(2):187-93
references: 18571762
references: Zhonghua Yu Fang Yi Xue Za Zhi. 2007 Jun;41 Suppl:30-4
references: 17767854
references: Tumour Biol. 2012 Oct;33(5):1341-8
references: 22457050
references: Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):461-6
references: 11352855
references: N Engl J Med. 2008 Sep 25;359(13):1367-80
references: 18815398
references: Cancer Lett. 2001 Nov 28;173(2):155-62
references: 11597790
references: Nat Rev Cancer. 2007 Oct;7(10):778-90
references: 17882278
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120